Engineering the cure for autoimmune diseases
At RheumaGen, we are engineering a new class of therapeutics to cure common autoimmune diseases. Our vision is to make possible for patients what no one thought could be achieved through editing the HLA, or “immune gene”: transforming autoimmunity.
Creating a Cure
RheumaGen is developing a breakthrough class of cell and gene therapies designed to cure autoimmune diseases at their source. The company is focused on editing the human leukocyte antigen (HLA), or “immune gene,” so that the immune system does not attack healthy cells.
Transformative Therapeutic Approach
RheumaGen is pioneering the first one-time, curative cell and gene therapies for refractory or treatment-resistant rheumatoid arthritis (RA) and other autoimmune diseases, such as progressive forms of multiple sclerosis, type 1 diabetes, and ankylosing spondylitis.
Dedicated to Patients in Need
RheumaGen was founded to relieve the burden that individuals suffering from autoimmune diseases have carried for so long. Mindful also of our own family members who are patients, we are not interested in incremental improvements. We seek cures; we seek remission.